Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

VWA5A antibody

VWA5A Reactivity: Human WB, ELISA, IHC Host: Rabbit Polyclonal unconjugated
Catalog No. ABIN7240895
  • Target See all VWA5A Antibodies
    VWA5A (Von Willebrand Factor A Domain Containing 5A (VWA5A))
    Reactivity
    • 24
    • 7
    • 6
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    Human
    Host
    • 21
    • 4
    Rabbit
    Clonality
    • 24
    • 1
    Polyclonal
    Conjugate
    • 15
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This VWA5A antibody is un-conjugated
    Application
    • 14
    • 8
    • 5
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
    Characteristics
    Polyclonal Antibody
    Purification
    Affinity purification
    Immunogen
    Recombinant protein of human VWA5A
    Isotype
    IgG
  • Application Notes
    WB 1:500-1:2000, IHC 1:100-1:300
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    0.5 mg/mL
    Buffer
    PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    -20 °C
    Storage Comment
    Store at -20°C. Avoid freeze / thaw cycles.
  • Target
    VWA5A (Von Willebrand Factor A Domain Containing 5A (VWA5A))
    Alternative Name
    VWA5A (VWA5A Products)
    Background
    VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80 % of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A.
    Molecular Weight
    86 kDa
    UniProt
    O00534
You are here:
Support